var data={"title":"Clostridium difficile and probiotics","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Clostridium difficile and probiotics</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/contributors\" class=\"contributor contributor_credentials\">Lisa E Davidson, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/contributors\" class=\"contributor contributor_credentials\">Patricia L Hibberd, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/contributors\" class=\"contributor contributor_credentials\">Stephen B Calderwood, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/contributors\" class=\"contributor contributor_credentials\">Elinor L Baron, MD, DTMH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 29, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Clostridium difficile </em>is an anaerobic, gram-positive, spore-forming bacillus that colonizes the intestinal tract after alteration of the normal gastrointestinal flora, usually by antibiotic therapy [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/1\" class=\"abstract_t\">1</a>]. Acquisition of spores usually occurs after exposure in the healthcare setting; spores are also ubiquitous in the soil and environment.</p><p>The normal gut flora and host immune responses work together to prevent spore germination, spore proliferation, and toxin production. Exposure to antibiotics is the most common risk factor resulting in development of active disease due to disruption of the gut microbiome and host immune responses.</p><p><em>C. difficile </em>causes a range of illness from mild diarrhea to pseudomembranous colitis and death. The frequency and severity of <em>C. difficile&ndash;</em>associated diarrhea (CDAD) are increasing as are relapsed disease and infection refractory to standard antibiotic therapy. (See <a href=\"topic.htm?path=clostridium-difficile-infection-in-adults-epidemiology-microbiology-and-pathophysiology\" class=\"medical medical_review\">&quot;Clostridium difficile infection in adults: Epidemiology, microbiology, and pathophysiology&quot;</a> and <a href=\"topic.htm?path=clostridium-difficile-infection-in-adults-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Clostridium difficile infection in adults: Clinical manifestations and diagnosis&quot;</a> and <a href=\"topic.htm?path=clostridium-difficile-infection-in-adults-treatment-and-prevention\" class=\"medical medical_review\">&quot;Clostridium difficile infection in adults: Treatment and prevention&quot;</a>.)</p><p>Probiotics are live, nonpathogenic bacteria capable of colonizing the colonic mucosa [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/2\" class=\"abstract_t\">2</a>]. Most probiotics are sold in fermented foods or dairy products as formulations. The most common probiotics include strains of <a href=\"topic.htm?path=lactobacillus-drug-information\" class=\"drug drug_general\">Lactobacillus</a> or <em>Bifidobacteria</em>, which are part of the normal gastrointestinal microbiota [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/3-7\" class=\"abstract_t\">3-7</a>]. <a href=\"topic.htm?path=saccharomyces-boulardii-drug-information\" class=\"drug drug_general\">Saccharomyces boulardii</a> is a yeast (fungal) probiotic agent [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/8\" class=\"abstract_t\">8</a>]. The alteration of gut microflora in the setting of CDAD has raised interest in a potential role for probiotics to restore a diverse intestinal microflora after disruption by antimicrobial therapy and CDAD [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/9\" class=\"abstract_t\">9</a>].</p><p>The role of probiotics for treatment and prevention of <em>C. difficile</em> will be reviewed here. The role of probiotics for antibiotic-associated diarrhea and other gastrointestinal diseases is discussed in detail separately. (See <a href=\"topic.htm?path=probiotics-for-gastrointestinal-diseases\" class=\"medical medical_review\">&quot;Probiotics for gastrointestinal diseases&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">MECHANISMS OF PROBIOTICS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Probiotics may be effective for prevention and treatment of <em>C. difficile</em>&ndash;associated diarrhea (CDAD) by means of several mechanisms:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Alteration of intestinal flora &ndash; The gastrointestinal tract is colonized by a complex balance of diverse microorganisms. Administration of antibiotics disrupts this balance and is a key factor in the pathogenesis of <em>C. difficile</em> colonization and disease. Patients with recurrent CDAD have markedly diminished bacterial diversity compared with controls [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/10\" class=\"abstract_t\">10</a>]. Most probiotics colonize the gut temporarily, producing bactericidal acids and peptides and promoting &quot;competition&quot; among microbes by competing for nutrients and epithelial adhesion. These effects appear to reduce the favorability of the environment for <em>C. difficile</em> [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/11-13\" class=\"abstract_t\">11-13</a>]. Both Lactobacilli [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/14\" class=\"abstract_t\">14</a>] and <em>S. boulardii</em> [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/15\" class=\"abstract_t\">15</a>] have been shown to suppress the growth of <em>C. difficile</em> in hamsters.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antimicrobial activity &ndash; Bacteria in probiotic preparations produce acids that lower the pH of the local gut environment as well as toxins that inhibit the growth of other bacteria [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/16\" class=\"abstract_t\">16</a>]. <em>S. boulardii</em> has been shown in vitro to secrete a protease that inhibits binding of enterotoxin A [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/17-19\" class=\"abstract_t\">17-19</a>], and <em>Lactococcus lactis</em> has been shown to secrete a cationic peptide that has antimicrobial activity against several strains of <em>C. difficile</em> in vitro [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/20\" class=\"abstract_t\">20</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intestinal barrier protection &ndash; The initial site of interaction between commensal and pathogenic bacteria in the human host is the gut epithelium. Probiotics may be capable of interfering with the binding of <em>C. difficile</em> toxins A and B to intestinal epithelial cells [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/18,21\" class=\"abstract_t\">18,21</a>]. In animal models and in vitro, probiotic strains have been shown to inhibit adhesion and decrease invasion of pathogenic organisms to the colonic epithelium [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/22-26\" class=\"abstract_t\">22-26</a>]. Specifically, Lactobacilli increase expression of intestinal mucins [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/27,28\" class=\"abstract_t\">27,28</a>] and decrease bacterial translocation [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/29-31\" class=\"abstract_t\">29-31</a>]. Several probiotic preparations, including <a href=\"topic.htm?path=lactobacillus-drug-information\" class=\"drug drug_general\">Lactobacillus</a> rhamnosus GG [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/32\" class=\"abstract_t\">32</a>], <em>Bifidobacterium breve</em> [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/33\" class=\"abstract_t\">33</a>], and <em>Streptococcus thermophilus</em> [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/33\" class=\"abstract_t\">33</a>], have been shown in animal models to stabilize gut permeability. In vitro studies have also demonstrated the ability of <em>S. boulardii</em> to inhibit adherence of <em>C. difficile</em> [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/34\" class=\"abstract_t\">34</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Immunomodulation &ndash; Probiotics modulate both the innate and adaptive immune systems by stimulating toll-like receptors [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/35-37\" class=\"abstract_t\">35-37</a>] and upregulating cytokine expression in dendritic cells and peripheral blood monocytes [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/38,39\" class=\"abstract_t\">38,39</a>]. Ingestion of Lactobacilli has been associated with enhanced phagocytic activity [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/40\" class=\"abstract_t\">40</a>]. In addition, several strains of <a href=\"topic.htm?path=lactobacillus-drug-information\" class=\"drug drug_general\">Lactobacillus</a> [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/41-43\" class=\"abstract_t\">41-43</a>], <em>Bifidobacterium</em> [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/44,45\" class=\"abstract_t\">44,45</a>], and <em>Sacchromyces</em> [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/46,47\" class=\"abstract_t\">46,47</a>] have been associated with increased immunoglobulin A secretion in both stool and serum.</p><p/><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">USE OF PROBIOTICS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinical role of probiotics for <em>C. difficile</em>&ndash;associated diarrhea (CDAD) treatment and prevention is an evolving area of study [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/48-59\" class=\"abstract_t\">48-59</a>]. Probiotics vary in their capacity to resist gastric and bile acids, colonize the lower intestinal tract, and influence cytokine secretion [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/25,36,60\" class=\"abstract_t\">25,36,60</a>]. Therefore, it is difficult to generalize findings observed with one probiotic species (eg, product, dose, duration) to other probiotic species or combinations.</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Prevention of CDAD</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We do not favor administration of adjunctive probiotics for routine treatment of CDAD. Thus far, no randomized trials have demonstrated benefit associated with routine probiotic administration for prevention of CDAD [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/61\" class=\"abstract_t\">61</a>]; some meta-analyses suggest that use of probiotics may be beneficial for prevention of CDAD [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/62-68\" class=\"abstract_t\">62-68</a>].</p><p>One randomized trial including more than 2900 adults with antibiotic exposure noted no risk reduction among those who received a multistrain preparation of <a href=\"topic.htm?path=lactobacillus-drug-information\" class=\"drug drug_general\">Lactobacillus</a> acidophilus and <em>Bifidobacterium bifidum</em> (relative risk [RR] 0.71; 95% CI 0.34-1.47) [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/69\" class=\"abstract_t\">69</a>]. Another randomized trial including 477 hospitalized patients found no evidence of an effect of <em>S. boulardii </em>for prevention of CDAD; it was stopped early for futility [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/70\" class=\"abstract_t\">70</a>].</p><p>In a meta-analysis including 20 randomized trials and more than 3800 patients, probiotics reduced the incidence of CDAD by 66 percent, corresponding to a pooled relative risk of 0.34 (95% CI 0.24-0.49) [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/62\" class=\"abstract_t\">62</a>]. Similarly, in a systematic review including 19 randomized trials and more than 6200 patients, the pooled relative risk of CDAD in patients receiving probiotics was 0.42 (95% CI 0.30-0.57) [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/63\" class=\"abstract_t\">63</a>]. In both of these analysis, the authors estimate that administration of probiotics to patients receiving antibiotics would prevent 23 to 144 cases per 1000 patients. However, the incidence of CDAD applied in this calculation is likely an overestimation, and true outcomes are likely to be variable dependent upon regional rates. (See <a href=\"topic.htm?path=clostridium-difficile-infection-in-adults-epidemiology-microbiology-and-pathophysiology\" class=\"medical medical_review\">&quot;Clostridium difficile infection in adults: Epidemiology, microbiology, and pathophysiology&quot;</a>.)</p><p>The strain, dose, and duration of probiotic used in the above studies varied widely. In designing future studies of probiotics for CDAD, it will be important to consider the different probiotic strains used and standardized probiotic dosing. In the meantime, if probiotics are used for prevention of CDAD, treatment should consist only of regimens with demonstrated efficacy (<a href=\"image.htm?imageKey=ID%2F50560\" class=\"graphic graphic_table graphicRef50560 \">table 1</a>).</p><p class=\"headingAnchor\" id=\"H12810765\"><span class=\"h2\">Treatment of CDAD</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Probiotics may also be useful for treatment of non-severe CDAD, particularly in the setting of recurrent disease, although data are limited [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/48,49\" class=\"abstract_t\">48,49</a>]. Two meta-analyses published in 2012 evaluating the efficacy of probiotics for the treatment of antibiotic-associated diarrhea suggested a benefit of probiotics for treatment of CDAD [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/65,66\" class=\"abstract_t\">65,66</a>], although few of the trials included were specifically powered to evaluate CDAD. Prior to these studies, the authors of a 2008 Cochrane review of probiotics for the treatment of CDAD including four randomized trials concluded that there was insufficient evidence to recommend probiotics as an adjunct to antimicrobial therapy for treatment of CDAD [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/49\" class=\"abstract_t\">49</a>].</p><p>These findings suggest that probiotics may be a useful adjunctive therapy to antimicrobial therapy for CDAD in patients with nonsevere recurrent disease as long as there are no significant comorbidities. (See <a href=\"#H6\" class=\"local\">'Safety'</a> below.)</p><p>Most trials of probiotics for the treatment of CDI exclude immunocompromised and severely ill patients [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/69,71\" class=\"abstract_t\">69,71</a>]. Thus far, there are no data supporting a role for probiotics in treatment of severe CDAD.</p><p class=\"headingAnchor\" id=\"H12811550\"><span class=\"h2\">Choice of probiotic agent</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Administration of probiotics for prevention or treatment of CDAD should consist only of regimens with demonstrated efficacy (<a href=\"image.htm?imageKey=ID%2F50560\" class=\"graphic graphic_table graphicRef50560 \">table 1</a>). Thus far, the cumulative data suggest that the most useful probiotic agents for prevention of CDAD include combination <em>L. acidophilus</em> and <a href=\"topic.htm?path=lactobacillus-drug-information\" class=\"drug drug_general\">Lactobacillus</a> <em>casei</em>, other mixed species, <em>S. boulardii</em>, or <em>L. rhamnosus</em> [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/71\" class=\"abstract_t\">71</a>]. In addition, a dosage of &gt;10 billion colony-forming units per day may be more effective than lower doses.</p><p>Interest in the role of probiotics for treatment of recurrent disease was initially raised by a study of 124 patients with CDAD randomized to receive four weeks of <em>S. boulardii </em>or placebo (in addition to treatment with <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a> or <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a>) [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/54\" class=\"abstract_t\">54</a>]. Patients with a history of recurrent CDAD had a lower rate of treatment failure with <em>S. boulardii</em> than with placebo (19.3 versus 64.7 percent). Among patients with an initial episode of CDAD, the failure rate was the same in both groups. Subsequently, a 2006 meta-analysis of probiotics for the treatment of CDAD including six randomized controlled trials involving 354 patients noted that <em>S. boulardii</em> was the only probiotic agent with efficacy for reducing recurrence of CDAD [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/48\" class=\"abstract_t\">48</a>].</p><p>Further evaluation is needed to fully evaluate the utility of <a href=\"topic.htm?path=lactobacillus-drug-information\" class=\"drug drug_general\">Lactobacillus</a> for treatment of CDAD. A systematic review and meta-analysis that included four trials (one pediatric, three adult) found no significant benefit of <em>Lactobacillus rhamnosus</em> GG for the prevention of CDI [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/72\" class=\"abstract_t\">72</a>]. Several small studies have evaluated <em>L. rhamnosus</em> GG; these did not demonstrate benefit, although they were small in size and likely underpowered to detect an effect [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/8,50-52,73,74\" class=\"abstract_t\">8,50-52,73,74</a>].</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">SAFETY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Probiotics are regulated as a dietary supplement; unlike drugs or biological products, there has been no requirement to demonstrate safety or manufacturing consistencies of probiotics sold to consumers. Therefore, cases of probiotic-associated bacteremia or fungemia may be underreported or difficult to assess from the literature.</p><p>A small number of case reports describing bacteremia or fungemia attributed to probiotic administration have been reported, although none have been noted in clinical trials [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/75\" class=\"abstract_t\">75</a>]. The probiotics most frequently associated with adverse outcomes are <em>S. boulardii</em> and <em>L. rhamnosus</em> GG [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/73-76\" class=\"abstract_t\">73-76</a>]. In most cases, patients who developed bacteremia or fungemia in the setting of probiotic administration had severe comorbidities, were on immunosuppressive medication, had recent surgical intervention, or had recent prolonged hospitalization. Of note, two cases of <em>S. boulardii</em> fungemia occurred in patients not receiving probiotics and were attributed to transmission by healthcare workers caring for patients who were taking <em>S. boulardii</em> [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/73,74\" class=\"abstract_t\">73,74</a>].</p><p>Use of probiotics in the setting of pancreatitis has been noted to increase mortality due to bowel ischemia [<a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/77\" class=\"abstract_t\">77</a>]. (See <a href=\"topic.htm?path=probiotics-for-gastrointestinal-diseases#H15\" class=\"medical medical_review\">&quot;Probiotics for gastrointestinal diseases&quot;, section on 'Pancreatitis'</a>.)</p><p class=\"headingAnchor\" id=\"H2457972732\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-clostridium-difficile-infection\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Clostridium difficile infection&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topics (see <a href=\"topic.htm?path=antibiotic-associated-diarrhea-c-difficile-infection-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Antibiotic-associated diarrhea (C. difficile infection) (The Basics)&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beyond the Basics topics (see <a href=\"topic.htm?path=antibiotic-associated-diarrhea-caused-by-clostridium-difficile-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Antibiotic-associated diarrhea caused by Clostridium difficile (Beyond the Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Probiotics are live, nonpathogenic bacteria capable of colonizing the colonic mucosa. The alteration of gut microflora in the setting of <em>Clostridium difficile</em>&ndash;associated diarrhea (CDAD) has raised interest in a potential role for use of probiotics to restore a diverse intestinal microflora after disruption by antimicrobial therapy and CDAD. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Mechanisms of probiotics include alteration of intestinal flora, antimicrobial activity, intestinal barrier protection, and immunomodulation. (See <a href=\"#H2\" class=\"local\">'Mechanisms of probiotics'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients receiving antibiotics who are felt to be at increased risk for CDAD, we suggest coadministration of probiotics for prevention of CDAD (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). Factors for consideration include prolonged duration of antibiotic therapy, local incidence of CDAD, and individual patient characteristics. (See <a href=\"#H5\" class=\"local\">'Prevention of CDAD'</a> above and <a href=\"topic.htm?path=clostridium-difficile-infection-in-adults-epidemiology-microbiology-and-pathophysiology#H402654\" class=\"medical medical_review\">&quot;Clostridium difficile infection in adults: Epidemiology, microbiology, and pathophysiology&quot;, section on 'Risk factors'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Further studies are needed to compare the probiotic strains and dosing for both the prevention and treatment of CDAD. Regimens with demonstrated efficacy for prevention of CDAD are summarized in the Table (<a href=\"image.htm?imageKey=ID%2F50560\" class=\"graphic graphic_table graphicRef50560 \">table 1</a>). (See <a href=\"#H12811550\" class=\"local\">'Choice of probiotic agent'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest NOT administering adjunctive probiotics for routine treatment of CDAD (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Use of probiotics may be reasonable in patients with recurrent disease that is not severe, as long as there are no significant comorbidities. Regimens with demonstrated efficacy are summarized in the Table (<a href=\"image.htm?imageKey=ID%2F50560\" class=\"graphic graphic_table graphicRef50560 \">table 1</a>). (See <a href=\"#H12810765\" class=\"local\">'Treatment of CDAD'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A small number of case reports describing bacteremia or fungemia attributed to probiotics have been reported; <a href=\"topic.htm?path=saccharomyces-boulardii-drug-information\" class=\"drug drug_general\">Saccharomyces boulardii</a> and <a href=\"topic.htm?path=lactobacillus-drug-information\" class=\"drug drug_general\">Lactobacillus</a> rhamnosus GG are the most common organisms. In almost all cases, patients who developed bacteremia or fungemia in the setting of probiotic therapy had severe comorbidities, were on immunosuppressive medication, had recent surgical intervention, or had recent prolonged hospitalization. (See <a href=\"#H6\" class=\"local\">'Safety'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/1\" class=\"nounderline abstract_t\">Bartlett JG. Historical perspectives on studies of Clostridium difficile and C. difficile infection. Clin Infect Dis 2008; 46 Suppl 1:S4.</a></li><li class=\"breakAll\">Food and Agriculture Organization of the United Nations and World Health Organization. Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria. Available at: ftp://ftp.fao.org/es/esn/food/probio_report_en.pdf (Accessed on November 19, 2008).</li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/3\" class=\"nounderline abstract_t\">Saarela M, Mogensen G, Fond&eacute;n R, et al. Probiotic bacteria: safety, functional and technological properties. J Biotechnol 2000; 84:197.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/4\" class=\"nounderline abstract_t\">Heller KJ. Probiotic bacteria in fermented foods: product characteristics and starter organisms. Am J Clin Nutr 2001; 73:374S.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/5\" class=\"nounderline abstract_t\">Mattia A, Merker R. Regulation of probiotic substances as ingredients in foods: premarket approval or &quot;generally recognized as safe&quot; notification. Clin Infect Dis 2008; 46 Suppl 2:S115.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/6\" class=\"nounderline abstract_t\">Ishibashi N, Yamazaki S. Probiotics and safety. Am J Clin Nutr 2001; 73:465S.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/7\" class=\"nounderline abstract_t\">Tuohy KM, Probert HM, Smejkal CW, Gibson GR. Using probiotics and prebiotics to improve gut health. Drug Discov Today 2003; 8:692.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/8\" class=\"nounderline abstract_t\">Edwards-Ingram L, Gitsham P, Burton N, et al. Genotypic and physiological characterization of Saccharomyces boulardii, the probiotic strain of Saccharomyces cerevisiae. Appl Environ Microbiol 2007; 73:2458.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/9\" class=\"nounderline abstract_t\">Surawicz CM. Role of probiotics in antibiotic-associated diarrhea, Clostridium difficile-associated diarrhea, and recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol 2008; 42 Suppl 2:S64.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/10\" class=\"nounderline abstract_t\">Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008; 197:435.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/11\" class=\"nounderline abstract_t\">Orrhage K, Sj&ouml;stedt S, Nord CE. Effect of supplements with lactic acid bacteria and oligofructose on the intestinal microflora during administration of cefpodoxime proxetil. J Antimicrob Chemother 2000; 46:603.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/12\" class=\"nounderline abstract_t\">Hopkins MJ, Macfarlane GT. Nondigestible oligosaccharides enhance bacterial colonization resistance against Clostridium difficile in vitro. Appl Environ Microbiol 2003; 69:1920.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/13\" class=\"nounderline abstract_t\">Wullt M, Johansson Hagsl&auml;tt ML, Odenholt I, Berggren A. Lactobacillus plantarum 299v enhances the concentrations of fecal short-chain fatty acids in patients with recurrent clostridium difficile-associated diarrhea. Dig Dis Sci 2007; 52:2082.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/14\" class=\"nounderline abstract_t\">Naaber P, Mikelsaar M. Interactions between Lactobacilli and antibiotic-associated diarrhea. Adv Appl Microbiol 2004; 54:231.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/15\" class=\"nounderline abstract_t\">Elmer GW, McFarland LV. Suppression by Saccharomyces boulardii of toxigenic Clostridium difficile overgrowth after vancomycin treatment in hamsters. Antimicrob Agents Chemother 1987; 31:129.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/16\" class=\"nounderline abstract_t\">Gill HS. Probiotics to enhance anti-infective defences in the gastrointestinal tract. Best Pract Res Clin Gastroenterol 2003; 17:755.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/17\" class=\"nounderline abstract_t\">Pothoulakis C, Kelly CP, Joshi MA, et al. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 1993; 104:1108.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/18\" class=\"nounderline abstract_t\">Castagliuolo I, Riegler MF, Valenick L, et al. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect Immun 1999; 67:302.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/19\" class=\"nounderline abstract_t\">Castagliuolo I, LaMont JT, Nikulasson ST, Pothoulakis C. Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect Immun 1996; 64:5225.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/20\" class=\"nounderline abstract_t\">Rea MC, Clayton E, O'Connor PM, et al. Antimicrobial activity of lacticin 3,147 against clinical Clostridium difficile strains. J Med Microbiol 2007; 56:940.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/21\" class=\"nounderline abstract_t\">Banerjee P, Merkel GJ, Bhunia AK. Lactobacillus delbrueckii ssp. bulgaricus B-30892 can inhibit cytotoxic effects and adhesion of pathogenic Clostridium difficile to Caco-2 cells. Gut Pathog 2009; 1:8.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/22\" class=\"nounderline abstract_t\">Bernet MF, Brassart D, Neeser JR, Servin AL. Lactobacillus acidophilus LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. Gut 1994; 35:483.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/23\" class=\"nounderline abstract_t\">Gopal PK, Prasad J, Smart J, Gill HS. In vitro adherence properties of Lactobacillus rhamnosus DR20 and Bifidobacterium lactis DR10 strains and their antagonistic activity against an enterotoxigenic Escherichia coli. Int J Food Microbiol 2001; 67:207.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/24\" class=\"nounderline abstract_t\">Bernet-Camard MF, Li&eacute;vin V, Brassart D, et al. The human Lactobacillus acidophilus strain LA1 secretes a nonbacteriocin antibacterial substance(s) active in vitro and in vivo. Appl Environ Microbiol 1997; 63:2747.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/25\" class=\"nounderline abstract_t\">Kalliom&auml;ki MA, Walker WA. Physiologic and pathologic interactions of bacteria with gastrointestinal epithelium. Gastroenterol Clin North Am 2005; 34:383.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/26\" class=\"nounderline abstract_t\">Hudault S, Li&eacute;vin V, Bernet-Camard MF, Servin AL. Antagonistic activity exerted in vitro and in vivo by Lactobacillus casei (strain GG) against Salmonella typhimurium C5 infection. Appl Environ Microbiol 1997; 63:513.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/27\" class=\"nounderline abstract_t\">Mack DR, Michail S, Wei S, et al. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol 1999; 276:G941.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/28\" class=\"nounderline abstract_t\">Madsen K, Cornish A, Soper P, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001; 121:580.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/29\" class=\"nounderline abstract_t\">Dong MY, Chang TW, Gorbach SL. Effects of feeding lactobacillus GG on lethal irradiation in mice. Diagn Microbiol Infect Dis 1987; 7:1.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/30\" class=\"nounderline abstract_t\">Naaber P, Mikelsaar RH, Salminen S, Mikelsaar M. Bacterial translocation, intestinal microflora and morphological changes of intestinal mucosa in experimental models of Clostridium difficile infection. J Med Microbiol 1998; 47:591.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/31\" class=\"nounderline abstract_t\">Otte JM, Podolsky DK. Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am J Physiol Gastrointest Liver Physiol 2004; 286:G613.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/32\" class=\"nounderline abstract_t\">Isolauri E, Majamaa H, Arvola T, et al. Lactobacillus casei strain GG reverses increased intestinal permeability induced by cow milk in suckling rats. Gastroenterology 1993; 105:1643.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/33\" class=\"nounderline abstract_t\">Terpend K, Blaton MA, Candalh C, et al. Intestinal barrier function and cow's milk sensitization in guinea pigs fed milk or fermented milk. J Pediatr Gastroenterol Nutr 1999; 28:191.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/34\" class=\"nounderline abstract_t\">Tasteyre A, Barc MC, Karjalainen T, et al. Inhibition of in vitro cell adherence of Clostridium difficile by Saccharomyces boulardii. Microb Pathog 2002; 32:219.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/35\" class=\"nounderline abstract_t\">Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, et al. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004; 118:229.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/36\" class=\"nounderline abstract_t\">Lan JG, Cruickshank SM, Singh JC, et al. Different cytokine response of primary colonic epithelial cells to commensal bacteria. World J Gastroenterol 2005; 11:3375.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/37\" class=\"nounderline abstract_t\">Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004; 126:1620.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/38\" class=\"nounderline abstract_t\">Gill HS, Rutherfurd KJ, Cross ML, Gopal PK. Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HN019. Am J Clin Nutr 2001; 74:833.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/39\" class=\"nounderline abstract_t\">Sougioultzis S, Simeonidis S, Bhaskar KR, et al. Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression. Biochem Biophys Res Commun 2006; 343:69.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/40\" class=\"nounderline abstract_t\">Gill HS, Rutherfurd KJ, Cross ML. Dietary probiotic supplementation enhances natural killer cell activity in the elderly: an investigation of age-related immunological changes. J Clin Immunol 2001; 21:264.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/41\" class=\"nounderline abstract_t\">Kaila M, Isolauri E, Soppi E, et al. Enhancement of the circulating antibody secreting cell response in human diarrhea by a human Lactobacillus strain. Pediatr Res 1992; 32:141.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/42\" class=\"nounderline abstract_t\">Link-Amster H, Rochat F, Saudan KY, et al. Modulation of a specific humoral immune response and changes in intestinal flora mediated through fermented milk intake. FEMS Immunol Med Microbiol 1994; 10:55.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/43\" class=\"nounderline abstract_t\">Majamaa H, Isolauri E, Saxelin M, Vesikari T. Lactic acid bacteria in the treatment of acute rotavirus gastroenteritis. J Pediatr Gastroenterol Nutr 1995; 20:333.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/44\" class=\"nounderline abstract_t\">Fukushima Y, Kawata Y, Hara H, et al. Effect of a probiotic formula on intestinal immunoglobulin A production in healthy children. Int J Food Microbiol 1998; 42:39.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/45\" class=\"nounderline abstract_t\">Yasui H, Shida K, Matsuzaki T, Yokokura T. Immunomodulatory function of lactic acid bacteria. Antonie Van Leeuwenhoek 1999; 76:383.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/46\" class=\"nounderline abstract_t\">Buts JP, Bernasconi P, Van Craynest MP, et al. Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii. Pediatr Res 1986; 20:192.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/47\" class=\"nounderline abstract_t\">Qamar A, Aboudola S, Warny M, et al. Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Immun 2001; 69:2762.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/48\" class=\"nounderline abstract_t\">McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006; 101:812.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/49\" class=\"nounderline abstract_t\">Pillai A, Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev 2008; :CD004611.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/50\" class=\"nounderline abstract_t\">Biller JA, Katz AJ, Flores AF, et al. Treatment of recurrent Clostridium difficile colitis with Lactobacillus GG. J Pediatr Gastroenterol Nutr 1995; 21:224.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/51\" class=\"nounderline abstract_t\">Gorbach SL, Chang TW, Goldin B. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG. Lancet 1987; 2:1519.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/52\" class=\"nounderline abstract_t\">Bennett RG, Gorbach SL, Chang TW. Treatment of relapsing Clostridium difficile diarrhea with Lactobacillus GG. Nutr Today 1996; 31:35S.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/53\" class=\"nounderline abstract_t\">Schellenberg D, Bonington A, Champion CM, et al. Treatment of Clostridium difficile diarrhoea with brewer's yeast. Lancet 1994; 343:171.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/54\" class=\"nounderline abstract_t\">McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271:1913.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/55\" class=\"nounderline abstract_t\">Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000; 31:1012.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/56\" class=\"nounderline abstract_t\">Lawrence SJ, Korzenik JR, Mundy LM. Probiotics for recurrent Clostridium difficile disease. J Med Microbiol 2005; 54:905.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/57\" class=\"nounderline abstract_t\">Thomas MR, Litin SC, Osmon DR, et al. Lack of effect of Lactobacillus GG on antibiotic-associated diarrhea: a randomized, placebo-controlled trial. Mayo Clin Proc 2001; 76:883.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/58\" class=\"nounderline abstract_t\">Wullt M, Hagsl&auml;tt ML, Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand J Infect Dis 2003; 35:365.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/59\" class=\"nounderline abstract_t\">Pochapin M. The effect of probiotics on Clostridium difficile diarrhea. Am J Gastroenterol 2000; 95:S11.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/60\" class=\"nounderline abstract_t\">Gorbach SL. Probiotics and gastrointestinal health. Am J Gastroenterol 2000; 95:S2.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/61\" class=\"nounderline abstract_t\">McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018; 66:e1.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/62\" class=\"nounderline abstract_t\">Johnston BC, Ma SS, Goldenberg JZ, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med 2012; 157:878.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/63\" class=\"nounderline abstract_t\">Shen NT, Maw A, Tmanova LL, et al. Timely Use of Probiotics in Hospitalized Adults Prevents Clostridium difficile Infection: A Systematic Review With Meta-Regression Analysis. Gastroenterology 2017.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/64\" class=\"nounderline abstract_t\">Sinclair A, Xie X, Saab L, Dendukuri N. Lactobacillus probiotics in the prevention of diarrhea associated with Clostridium difficile: a systematic review and Bayesian hierarchical meta-analysis. CMAJ Open 2016; 4:E706.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/65\" class=\"nounderline abstract_t\">Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA 2012; 307:1959.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/66\" class=\"nounderline abstract_t\">Ritchie ML, Romanuk TN. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS One 2012; 7:e34938.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/67\" class=\"nounderline abstract_t\">Szajewska H, Ko&#322;odziej M. Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2015; 42:793.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/68\" class=\"nounderline abstract_t\">Goldenberg JZ, Yap C, Lytvyn L, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev 2017; 12:CD006095.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/69\" class=\"nounderline abstract_t\">Allen SJ, Wareham K, Wang D, et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2013; 382:1249.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/70\" class=\"nounderline abstract_t\">Ehrhardt S, Guo N, Hinz R, et al. Saccharomyces boulardii to Prevent Antibiotic-Associated Diarrhea: A Randomized, Double-Masked, Placebo-Controlled Trial. Open Forum Infect Dis 2016; 3:ofw011.</a></li><li class=\"breakAll\">Johnston BC, Ma SS, Goldenburg JZ, et al.  Probiotics for the prevention of clostridium difficile&ndash;associated diarrhea:A systematic review and meta-analysis. Ann Int Med 2012. https://annals.org/article.aspx?articleid=1390418 (Accessed on December 03, 2012).</li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/72\" class=\"nounderline abstract_t\">Szajewska H, Ko&#322;odziej M. Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults. Aliment Pharmacol Ther 2015; 42:1149.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/73\" class=\"nounderline abstract_t\">Belet N, Dalgi&ccedil; N, Oncel S, et al. Catheter-related fungemia caused by Saccharomyces cerevisiae in a newborn. Pediatr Infect Dis J 2005; 24:1125.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/74\" class=\"nounderline abstract_t\">Graf C, Gavazzi G. Saccharomyces cerevisiae fungemia in an immunocompromised patient not treated with Saccharomyces boulardii preparation. J Infect 2007; 54:310.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/75\" class=\"nounderline abstract_t\">Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr 2006; 83:1256.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/76\" class=\"nounderline abstract_t\">Mu&ntilde;oz P, Bouza E, Cuenca-Estrella M, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005; 40:1625.</a></li><li><a href=\"https://www.uptodate.com/contents/clostridium-difficile-and-probiotics/abstract/77\" class=\"nounderline abstract_t\">Besselink MG, van Santvoort HC, Buskens E, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371:651.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 2705 Version 27.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H8\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">MECHANISMS OF PROBIOTICS</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">USE OF PROBIOTICS</a><ul><li><a href=\"#H5\" id=\"outline-link-H5\">Prevention of CDAD</a></li><li><a href=\"#H12810765\" id=\"outline-link-H12810765\">Treatment of CDAD</a></li><li><a href=\"#H12811550\" id=\"outline-link-H12811550\">Choice of probiotic agent</a></li></ul></li><li><a href=\"#H6\" id=\"outline-link-H6\">SAFETY</a></li><li><a href=\"#H2457972732\" id=\"outline-link-H2457972732\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H7\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/2705|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ID/50560\" class=\"graphic graphic_table\">- Probiotic regimens</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clostridium-difficile-infection-in-adults-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Clostridium difficile infection in adults: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clostridium-difficile-infection-in-adults-epidemiology-microbiology-and-pathophysiology\" class=\"medical medical_review\">Clostridium difficile infection in adults: Epidemiology, microbiology, and pathophysiology</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clostridium-difficile-infection-in-adults-treatment-and-prevention\" class=\"medical medical_review\">Clostridium difficile infection in adults: Treatment and prevention</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=antibiotic-associated-diarrhea-c-difficile-infection-the-basics\" class=\"medical medical_basics\">Patient education: Antibiotic-associated diarrhea (C. difficile infection) (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=antibiotic-associated-diarrhea-caused-by-clostridium-difficile-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Antibiotic-associated diarrhea caused by Clostridium difficile (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=probiotics-for-gastrointestinal-diseases\" class=\"medical medical_review\">Probiotics for gastrointestinal diseases</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-clostridium-difficile-infection\" class=\"medical medical_society_guidelines\">Society guideline links: Clostridium difficile infection</a></li></ul></div></div>","javascript":null}